The role of statins in reducing the risk of no-slow-reflow by coronary revascularisation
- Authors: Khripunova A.1, Sazanov G.2, Znamenskaya I.1, Khripunova I.1
-
Affiliations:
- Stavropol State Medical University
- Stavropol regional clinical hospital
- Issue: Vol 34, No 3 (2023)
- Pages: 49-51
- Section: Pharmacology
- URL: https://journals.rcsi.science/0236-3054/article/view/143013
- DOI: https://doi.org/10.29296/25877305-2023-03-09
- ID: 143013
Cite item
Abstract
Blood flow restoration by percutaneous coronary intervention (PCI) is currently one of the main approaches to the treatment of patients with acute myocardial infarction. However, suboptimal coronary reperfusion associated with microvascular obstruction (no-slow-reflow phenomenon) may occur in 30–60% of cases after PCI. This review presents an analysis of the effect of statin therapy on the risk of no-slow-reflow and clinical prognosis in patients after PCI.
Full Text
##article.viewOnOriginalSite##About the authors
A. Khripunova
Stavropol State Medical University
Author for correspondence.
Email: fktcz2007@yandex.ru
Associate Professor, Candidate of Medical Sciences
Russian Federation, StavropolG. Sazanov
Stavropol regional clinical hospital
Email: fktcz2007@yandex.ru
Russian Federation, Stavropol
I. Znamenskaya
Stavropol State Medical University
Email: fktcz2007@yandex.ru
Candidate of Medical Sciences
Russian Federation, StavropolI. Khripunova
Stavropol State Medical University
Email: fktcz2007@yandex.ru
Associate Professor, Candidate of Medical Sciences
Russian Federation, StavropolReferences
- Vyshlov E.V., Ryabov V.V. Coronary reperfusion in acute myocardial infarction. Tomsk: Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 2019; 196 р. (in Russ.).
- Writing Committee Members, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79 (2): e21–e129. doi: 10.1016/j.jacc.2021.09.006
- Ibanez B., James S., Agewall S. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39: 119–77. doi: 10.1093/eurheartj/ehx393
- TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985; 312 (14): 932–6. doi: 10.1056/NEJM198504043121437
- Niccoli G., Kharbanda R.K., Crea F. et al. No-reflow: Again prevention is better than treatment. Eur Heart J. 2010; 31 (20): 2449–55. doi: 10.1093/eurheartj/ehq299
- Kaul S. The “no reflow” phenomenon following acute myocardial infarction: Mechanisms and treatment options. J Cardiol. 2014; 64 (2): 77–85. doi: 10.1016/j.jjcc.2014.03.008
- Iskhakov M.M., Tagirova D.R., Gazizov N.V. et al. «No-Reflow» Phenomenon: Clinical Aspects of Reperfusion Failure. Kazan Medical Journal. 2015; 96 (3): 391–6 (in Russ.). doi: 10.17750/KMJ2015-391
- Tasar O., Karabay A.K., Oduncu V. et al. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019; 30 (4): 270–6. doi: 10.1097/MCA.0000000000000726
- Niccoli G., Burzotta F., Galiuto L. et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009; 54 (4): 281–92. doi: 10.1016/j.jacc.2009.03.054
- De Waha S., Patel M.R., Granger C.B. et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: An individual patient data pooled analysis from seven randomized trials. Eur Heart J. 2017; 38 (47): 3502–10. doi: 10.1093/eurheartj/ehx414
- Caiazzo G., Musci R.L., Frediani L. et al. State of the Art: No-Reflow Phenomenon. Cardiol Clin. 2020; 38 (4): 563–73. doi: 10.1016/j.ccl.2020.07.001
- Kaur G., Baghdasaryan P., Natarajan B. et al. Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon. Int J Angiol. 2021; 30 (1): 15–21. doi: 10.1055/s-0041-1725979
- Riksen N.P., Franke B., van den Broek P. et al. The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genom. 2007; 17 (7): 551–4. doi: 10.1097/FPC.0b013e32803fb78f
- Kloner R.A., King K.S., Harrington M.G. No-reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol. 2018; 315 (3): H550-H562. doi: 10.1152/ajpheart.00183.2018
- Faruk Akturk I., Arif Yalcin A., Biyik I. et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol. 2014; 62 (5): 389–97.
- Theilmeier G., Verhamme P., Dymarkowski M. et al. Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density. Circulation. 2002; 106 (9): 1140–6. doi: 10.1161/01.cir.0000026805.41747.54
- Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment im-proves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49 (12): 1272–8. doi: 10.1016/j.jacc.2007.02.025
- Yun K.H., Jeong M.H., Oh S.K. et al. The beneficial effect: of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009; 137 (3): 246–51. doi: 10.1016/j.ijcard.2008.06.055
- Ishii H., Ichimiya S., Kanashiro M. et al. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther. 2006; 28 (11): 1812–9. doi: 10.1016/j.clinthera.2006.11.003
- Chang S.M., Yazbek N., Lakkis N.M. Use of statins prior to percutane¬ous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv. 2004; 62 (2): 193–7. doi: 10.1002/ccd.20078
- Yun K.H., Shin I.S., Shin S.N. et al. Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention. Korean Circ J. 2011; 41 (8): 458–63. doi: 10.4070/kcj.2011.41.8.458
- Briguori C., Colombo A., Airoldi F. et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004; 25 (20): 1822–8. doi: 10.1016/j.ehj.2004.07.017
- Ebrahimi R., Saleh J., Toggart E. et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol. 2008; 20 (6): 292–5.
- Ray K.K., Cannon C.P., McCabe C.H. et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005; 46 (8): 1405–10. doi: 10.1016/j.jacc.2005.03.077
- Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285 (13): 1711–7. doi: 10.1001/jama.285.13.1711
- Kim J.-S., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: The STATIN STEMI trial. JACC Cardiovasc. Interv. 2010; 3 (3): 332–9. doi: 10.1016/j.jcin.2009.11.021
- Spencer F.A., Allegrone J., Goldberg R.J. et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004; 140 (11): 857–66. doi: 10.7326/0003-4819-140-11-200406010-00006
- Bauer T., Böhm M., Zahn R. et al. Effect of chronic statin pretreatment on hospital outcome in patients with acute non-ST-elevation myocardial infarction. J Cardiovasc Pharmacol. 2009; 53 (2): 132–6. doi: 10.1097/FJC.0b013e3181976a3c
- Annibali G., Scrocca I., Aranzulla T.C. et al. «No-Reflow» Phenomenon: A Contemporary Review. J Clin Med. 2022; 11 (8): 2233. doi: 10.3390/jcm11082233
- Alidoosti M., Lotfi R., Lotfi-Tokaldany M. et al. Correlates of the «No-Reflow» or «Slow-Flow» Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention. J Tehran Heart Cent. 2018; 13 (3): 108–14.
- Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21 (11): 1712–9. doi: 10.1161/hq1101.098486
- Sposito A.C., Chapman M.J. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002; 22 (10): 1524–34. doi: 10.1161/01.atv.0000032033.39301.6a
- Kurita A., Takashima H., Ando H. et al. Effects of eicosapentaenoic acid on peri-procedural (type IVa) myocardial infarction following elective coronary stenting. J Cardiol. 2015; 66 (2): 114–9. doi: 10.1016/j.jjcc.2014.09.004
- Prasad A., Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med. 2011; 364 (5): 453–64. doi: 10.1056/NEJMra0912134